Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pilot Study of the Impact of Rosuvastatin Administration on Residual Chronic Immune Activation Under Antiretroviral Therapy: CESAR (Crestor En Sus Des AntiRetroviraux)

Trial Profile

Pilot Study of the Impact of Rosuvastatin Administration on Residual Chronic Immune Activation Under Antiretroviral Therapy: CESAR (Crestor En Sus Des AntiRetroviraux)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rosuvastatin (Primary)
  • Indications HIV-1 infections
  • Focus Biomarker; Pharmacodynamics
  • Acronyms CESAR
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 13 Nov 2015 Status changed from recruiting to completed based on the full analysis set results published in the JAIDS.
    • 02 Nov 2015 Primary endpoint [Receptor activation (Coexpress activation markers: proportion of peripheral CD8 T cells that co-express the activation markers CD38 and HLA-DR.)] has not been met as per the results published in the JAIDS.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top